纵向分析在PARP抑制剂耐药的晚期乳腺癌中识别出共存的BRCA1/2回复突变及TP53BP1、RIF1和PAXIP1突变
对47例接受HRD靶向治疗进展的转移性BRCA1/2或PALB2突变乳腺癌患者进行纵向ctDNA突变和甲基化分析,BRCA1/2回复突变见于60%患者,是最常见的耐药形式;10例在临床进展前即检出回复突变,回复突变与更短至进展时间相关。新发现两种回复突变机制:伴内含子断点的BRCA1/2基因内缺失,以及形成新剪接受体位点的BRCA1/2基因内二次突变。TP53BP1、RIF1或PAXIP1功能缺失突变见于获得性耐药患者,偶与回复突变共存。
要点
- BRCA1/2回复突变见于60%患者,是最常见的耐药形式。
- 回复突变在10例中于临床进展前即从ctDNA检出。
- 回复突变与后续治疗开始前的至进展时间显著缩短相关。
核心结论
- 这些观察描绘了临床环境中HRD乳腺癌耐药候选驱动因素随时间的患病率,对临床管理和试验设计具有意义。
研究设计与样本
- 对47例接受HRD靶向治疗进展的转移性BRCA1、BRCA2或PALB2突变乳腺癌患者进行纵向循环肿瘤DNA突变和甲基化分析。
- 18例为原发耐药,29例为缓解后耐药。
- 使用>750基因内含子/外显子靶向测序面板对多个时间点(治疗前、治疗中和进展时)的ctDNA进行测序。
- 在可获得时,对匹配的肿瘤活检进行全外显子组和RNA测序,并评估核RAD51。
主要发现
- BRCA1/2回复突变见于60%患者,是最常见的耐药形式。
- 在10例中,回复突变在临床进展前即于ctDNA中检出。
- 鉴定出两种新的基于回复突变的机制:伴内含子断点的BRCA1/2基因内缺失,以及形成新剪接受体位点的BRCA1/2基因内二次突变,后者经体外小基因报告试验证实。
- 在开始后续治疗前检出回复突变时,回复突变与显著更短的至进展时间相关。
- 携带回复突变的肿瘤保留HRD突变特征,但基于RAD51状态具有功能性同源重组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Resistance to therapies that target homologous recombination deficiency (HRD) in breast cancer limits their overall effectiveness. Multiple, preclinically validated, mechanisms of resistance have been proposed, but their existence and relative frequency in clinical disease are unclear, as is how to target resistance. PATIENTS AND METHODS: Longitudinal mutation and methylation profiling of circulating tumour (ct)DNA was carried out in 47 patients with metastatic BRCA1-, BRCA2- or PALB2-mutant breast cancer treated with HRD-targeted therapy who developed progressive disease-18 patients had primary resistance and 29 exhibited response followed by resistance. ctDNA isolated at multiple time points in the patient treatment course (before, on-treatment and at progression) was sequenced using a novel >750-gene intron/exon targeted sequencing panel. Where available, matched tumour biopsies were whole exome and RNA sequenced and also used to assess nuclear RAD51. RESULTS: BRCA1/2 reversion mutations were present in 60% of patients and were the most prevalent form of resistance. In 10 cases, reversions were detected in ctDNA before clinical progression. Two new reversion-based mechanisms were identified: (i) intragenic BRCA1/2 deletions with intronic breakpoints; and (ii) intragenic BRCA1/2 secondary mutations that formed novel splice acceptor sites, the latter being confirmed by in vitro minigene reporter assays. When seen before commencing subsequent treatment, reversions were associated with significantly shorter time to progression. Tumours with reversions retained HRD mutational signatures but had functional homologous recombination based on RAD51 status. Although less frequent than reversions, nonreversion mechanisms [loss-of-function (LoF) mutations in TP53BP1, RIF1 or PAXIP1] were evident in patients with acquired resistance and occasionally coexisted with reversions, challenging the notion that singular resistance mechanisms emerge in each patient. CONCLUSIONS: These observations map the prevalence of candidate drivers of resistance across time in a clinical setting, information with implications for clinical management and trial design in HRD breast cancers.
引用
- Harvey-Jones E, Raghunandan M, Robbez-Masson L, et al. Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer. Ann Oncol. 2024. PMID: 38244928. doi:10.1016/j.annonc.2024.01.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。